Opportunity Information: Apply for RFA AA 14 001
Apply for RFA AA 14 001
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273 Alcohol Research Programs.
- This funding opportunity was created on Nov 5, 2013 and posted on Nov 5, 2013.
- Applicants must submit their applications by Jan 21, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $7,500,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Organizations holding an active NIAAA funded U10 are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10) funding opportunity (RFA-AA-14-001) was a National Institutes of Health (NIH) announcement from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) that supported the continuation and expansion of the long-running COGA research program. It was structured as a cooperative agreement (U10), which means NIH staff were expected to have substantial scientific involvement with the awardee beyond the typical level seen in standard research grants. The overall scientific purpose was to deepen understanding of the genetic and biological factors that contribute to alcohol dependence, while also improving the measurement of alcoholism-related traits and tracking outcomes over time in established COGA participants.
The FOA laid out several core scientific objectives. First, it aimed to identify genetic variants that influence susceptibility to alcohol dependence in both adults and adolescents, reflecting an interest in risk processes across development and not only in fully established adult alcohol use disorders. Second, it emphasized moving beyond discovery to biology by determining molecular and functional mechanisms for identified variants, pointing toward work that connects statistical genetic findings to pathways, gene function, and physiological consequences. Third, it explicitly called for identifying and characterizing gene-by-gene and gene-by-environment interactions, recognizing that alcoholism risk often arises from combined genetic effects and environmental exposures rather than single factors acting in isolation. Fourth, it prioritized the development and refinement of phenotypes to facilitate genetic analysis, meaning applicants were expected to improve the way alcoholism and related traits are defined and measured so that genetic signals can be detected more clearly. Fifth, it supported prospective studies of COGA probands, highlighting longitudinal follow-up as a major feature, with the intent to observe how risk unfolds over time and how early traits, exposures, and genetic profiles relate to later outcomes.
This was a limited competition announcement, meaning it was not open to the broad research community. Eligibility was restricted to organizations already holding an active NIAAA-funded U10 for COGA, effectively making this a continuation opportunity for the established COGA cooperative agreement team and infrastructure. Foreign institutions were not eligible, non-U.S. components of U.S. organizations were not eligible, and foreign components (as defined by NIH policy) were not allowed. In practice, the FOA was designed to keep the COGA effort cohesive and to ensure continuity of data collection, participant follow-up, and cross-site coordination within the existing consortium framework.
From an administrative standpoint, the opportunity was categorized as discretionary funding in the health area and did not require cost sharing or matching funds. NIH anticipated making a single award, with an estimated total funding level of $7,500,000. The program was associated with CFDA number 93.273 (Alcohol Research Programs). The FOA was posted on November 5, 2013, and had an original and current closing date of January 21, 2014, with an archive date of February 21, 2014, indicating it is no longer active but remains available for historical reference.
Overall, this FOA focused on advancing a major national collaborative resource for alcoholism genetics by combining large-scale human genetic analyses with improved phenotype definitions, mechanistic follow-up, interaction modeling (gene-by-gene and gene-by-environment), and prospective longitudinal tracking of participants. The cooperative agreement mechanism and limited eligibility underscored that the goal was not to start a new, unrelated project, but to sustain and further develop an established multi-site program with shared standards, centralized coordination, and ongoing NIH scientific partnership.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity was the Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10) funding opportunity, identified as RFA-AA-14-001. It was a National Institutes of Health (NIH) announcement from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to support the continuation and expansion of the long-running COGA research program.
Which NIH institute issued the announcement?
The announcement was issued by NIAAA, which is part of NIH.
What type of award mechanism did it use?
It used a cooperative agreement mechanism, specifically U10.
What does a U10 cooperative agreement mean in practice?
A U10 cooperative agreement indicates that NIH staff were expected to have substantial scientific involvement with the awardee beyond what is typical for standard research grants. The intent was active scientific partnership and coordination rather than a more hands-off grant relationship.
What was the overall scientific purpose of the FOA?
The overall purpose was to deepen understanding of the genetic and biological factors that contribute to alcohol dependence, improve the measurement of alcoholism-related traits, and track outcomes over time in established COGA participants.
What were the core scientific objectives described in the FOA?
The FOA emphasized multiple objectives: (1) identifying genetic variants influencing susceptibility to alcohol dependence in both adults and adolescents; (2) determining molecular and functional mechanisms for identified variants; (3) identifying and characterizing gene-by-gene and gene-by-environment interactions; (4) developing and refining phenotypes to facilitate genetic analysis; and (5) supporting prospective (longitudinal) studies of COGA probands.
Did the FOA focus only on adult alcohol dependence?
No. It explicitly included both adults and adolescents, reflecting interest in risk processes across development and not only in fully established adult alcohol use disorders.
How did the FOA address the gap between gene discovery and biology?
It emphasized determining molecular and functional mechanisms for identified genetic variants, pointing toward work that connects statistical genetic findings to pathways, gene function, and physiological consequences.
Were interaction effects part of the research priorities?
Yes. The FOA explicitly called for identifying and characterizing gene-by-gene and gene-by-environment interactions, recognizing that risk can arise from combined genetic effects and environmental exposures.
What did the FOA mean by developing or refining phenotypes?
It prioritized improving the way alcoholism and related traits are defined and measured so genetic signals can be detected and analyzed more clearly.
Did the FOA support longitudinal follow-up?
Yes. It supported prospective studies of COGA probands and highlighted longitudinal follow-up as a major feature, aiming to observe how risk unfolds over time and how early traits, exposures, and genetic profiles relate to later outcomes.
Was this an open competition?
No. This was a limited competition announcement, meaning it was not open to the broad research community.
Who was eligible to apply?
Eligibility was restricted to organizations already holding an active NIAAA-funded U10 for COGA. In effect, it functioned as a continuation opportunity for the established COGA cooperative agreement team and infrastructure.
Could a new organization without an active COGA U10 apply?
No. Based on the limited competition restriction, organizations without an active NIAAA-funded U10 for COGA were not eligible.
Were foreign institutions eligible?
No. Foreign institutions were not eligible.
Could a U.S. organization include a non-U.S. component?
No. Non-U.S. components of U.S. organizations were not eligible.
Were foreign components allowed under NIH policy definitions?
No. Foreign components (as defined by NIH policy) were not allowed.
How many awards did NIH anticipate making?
NIH anticipated making a single award.
What was the estimated total funding level?
The estimated total funding level was $7,500,000.
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching funds.
How was the opportunity categorized administratively?
It was categorized as discretionary funding in the health area.
What CFDA number was associated with this program?
The program was associated with CFDA number 93.273, Alcohol Research Programs.
What were the key dates for the FOA?
The FOA was posted on November 5, 2013. The original and current closing date was January 21, 2014. The archive date was February 21, 2014.
Is this FOA still active?
No. The closing date and archive date indicate the FOA is no longer active, though it remains available for historical reference.
Why was the FOA designed as a limited competition and cooperative agreement?
Based on the FOA description, the limited eligibility and U10 cooperative agreement structure were intended to sustain and further develop an established, cohesive multi-site COGA program with shared standards, centralized coordination, ongoing participant follow-up, and continued NIH scientific partnership, rather than starting unrelated new projects.
What kinds of research activities did the FOA emphasize overall?
It emphasized large-scale human genetic analyses, improved phenotype definitions, mechanistic follow-up to connect variants to biology, modeling of interaction effects (gene-by-gene and gene-by-environment), and prospective longitudinal tracking of established COGA participants.
Browse more opportunities from the same category: Health
Next opportunity: Projects of Special Merit Competition FY2014
Previous opportunity: Solid Waste Management Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AA 14 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AA 14 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25) Apply for PAR 13 384 Funding Number: PAR 13 384 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| LINKAGES HIV SERVICES FOR KEY POPULATIONS Apply for SOL OAA 14 000013 Funding Number: SOL OAA 14 000013 Agency: Agency for International Development Category: Health Funding Amount: $72,000,000 |
| Systems Strengthening for Health Commodities Apply for RFA 617 14 000001 Funding Number: RFA 617 14 000001 Agency: Uganda USAID Kampala Category: Health Funding Amount: Case Dependent |
| Evaluation and Administration Coordinating Center for the Low Cost, Pragmatic, Patient Centered Randomized Controlled Intervention Trials (R01) Apply for RFA HL 14 020 Funding Number: RFA HL 14 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical, Epidemiologic and Ecologic Factors Impacting the Burden and Distribution of Monkeypox in Tshuapa District, Democratic Republic of the Congo Apply for RFA CK 14 002 Funding Number: RFA CK 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (Collaborative R01) Apply for PAR 13 391 Funding Number: PAR 13 391 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01) Apply for PAR 13 392 Funding Number: PAR 13 392 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory and Developmental Grant to Improve Health Care Quality through Health Information Technology (IT) (R21) Apply for PA 14 001 Funding Number: PA 14 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $200,000 |
| Epidemiology, Prevention, and Treatment of Influenza and Other Respiratory Infections in a Malaria Endemic Area of Malawi with High HIV Prevalence Apply for RFA IP 14 002 Funding Number: RFA IP 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Advancing Patient Safety Implementation through Safe Medication Use Research (R18) Apply for PA 14 002 Funding Number: PA 14 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Collaborative Activities to Promote Metabolomics Research (Admin Supp) Apply for PA 14 003 Funding Number: PA 14 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Health Network Development Planning Program Apply for HRSA 14 043 Funding Number: HRSA 14 043 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| ATSDRs Program to Promote Localized Efforts To Reduce Environmental Exposure (APPLETREE) Apply for CDC RFA TS14 1403 Funding Number: CDC RFA TS14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| The Cooperative Re Engagement Controlled Trial (CoRECT) Apply for RFA PS 14 001 Funding Number: RFA PS 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,300,000 |
| Reduction of Malaria in U.S. Residents Returning from Overseas Travel to Malaria Endemic Countries Apply for RFA CK 14 004 Funding Number: RFA CK 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Service Area Competition Additional Area (SAC AA) Evergreen, AL Gualala, CA Tallahassee, FL Nashua, NH Waxahachie, Texas and Kenosha, WI Apply for HRSA 14 111 Funding Number: HRSA 14 111 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Advances in Patient Safety through Simulation Research (R18) Apply for PA 14 004 Funding Number: PA 14 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Continuum of Prevention, Care and Treatment of HIV/AIDS in Most at Risk Poupulations in Cameroon CHAMP Apply for RFA 624 14 000001 Funding Number: RFA 624 14 000001 Agency: Ghana USAID Accra Category: Health Funding Amount: $18,800,000 |
| Animal and Biological Material Resource Centers (P40) Apply for PAR 14 005 Funding Number: PAR 14 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Safety Learning Laboratories Innovative Design and Development to Improve Healthcare Delivery Systems (P30) Apply for RFA HS 14 005 Funding Number: RFA HS 14 005 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AA 14 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.